Sam Bankman-Fried’s Lawyers Request Stronger ADHD Medication for Trial
Lawyers representing Sam Bankman-Fried, the former CEO of FTX, have indicated that he may testify in his trial for fraud and conspiracy. In a letter to Judge Lewis Kaplan, they expressed concerns about their client’s inadequate dosage of Adderall, a medication used to treat ADHD.
The defense team is worried that Bankman-Fried’s inability to concentrate due to the lack of access to Adderall may hinder his participation in presenting the defense case. Adderall is commonly prescribed for individuals with Attention Deficit Hyperactivity Disorder.
Prosecution Expected to Conclude Soon
The prosecutors anticipate that their case will conclude on October 26. Afterward, the focus will shift to the defense team.
SBF Sunday night filing – rerequest for trial day Adderall so he can decide whether to testify: “as we approach the decision of whether Mr. Bankrnan-Fried will testify… because of his lack of access to Adderall he has not been able to concentrate” story coming https://t.co/uUXBcLMej9 pic.twitter.com/sjZKD6XUUh
— Inner City Press (@innercitypress) October 16, 2023
Bankman-Fried: The Battle For Medication
Bankman-Fried’s legal team has been advocating for a stronger dose of Adderall since he was remanded. They initially had some success, but encountered challenges during the trial. The defense attempted to resolve the issue with the Bureau of Prisons but received no response.
Seeking Solutions
Bankman-Fried currently receives a morning dose of Adderall that wears off before the jury assembles in court. He does not receive further doses until returning to the Brooklyn lockup at night. If a solution is not found soon, the defense team proposed a one-day adjournment to address the medication issue.
Hot Take: Concerns over ADHD Medication Impact on Trial
The trial of Sam Bankman-Fried for fraud and conspiracy has raised concerns about his access to adequate medication for his ADHD. His lawyers argue that the lack of proper doses of Adderall may affect his ability to concentrate and participate in presenting his defense. As the trial nears its conclusion, it remains to be seen how this medication issue will be resolved and its potential impact on the proceedings.
By
By
By
By
